Caribou Biosciences Inc
NASDAQ:CRBU

Watchlist Manager
Caribou Biosciences Inc Logo
Caribou Biosciences Inc
NASDAQ:CRBU
Watchlist
Price: 1.96 USD -14.41% Market Closed
Market Cap: 182.3m USD

Net Margin
Caribou Biosciences Inc

-1 490.8%
Current
-756%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 490.8%
=
Net Income
-147.9m
/
Revenue
9.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Caribou Biosciences Inc
NASDAQ:CRBU
182.3m USD
-1 491%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
132.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Caribou Biosciences Inc
Glance View

Market Cap
182.3m USD
Industry
Biotechnology

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.

CRBU Intrinsic Value
1.12 USD
Overvaluation 43%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 490.8%
=
Net Income
-147.9m
/
Revenue
9.9m
What is the Net Margin of Caribou Biosciences Inc?

Based on Caribou Biosciences Inc's most recent financial statements, the company has Net Margin of -1 490.8%.

Back to Top